FIELD: chemistry.
SUBSTANCE: invention relates to novel salt forms of a compound of formula 2 or a hydrate or solvate thereof. Compounds have selective inhibition properties of at least one epidermal growth factor receptor (EGFR) mutant compared to wild-type EGFR (EGFR WT). Mutant of epidermal growth factor receptor kinase (EGFR) receptors is an activating mutant, a deletion mutant, a mutation with a point mutation or a mutant selected from T790M, deIE746-A750, L858R and G719S. Salts of compound 2 are described by general formula
where n is 1 or 2; and X is hydrobromic acid, benzenesulphonic acid, camphorsulphonic acid, 1,2-ethane disulphonic acid, hydrochloric acid, maleic acid, methanesulphonic acid, naphthalene-2-sulphonic acid, 1,5-naphthalene disulphonic acid, oxalic acid, 4-toluenesulphonic acid or 2,4,6-trihydroxybenzoic acid. Also described are crystal forms of salts characterized by data of X-ray powder diffraction pattern.
EFFECT: compounds can be used in treating tumorous diseases, such as non-small-cell lung cancer.
31 cl, 87 dwg, 21 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | 2013 |
|
RU2673077C2 |
| 9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZATETRACYCLO[18.3.1.1(2,5). 1(14,18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | 2010 |
|
RU2543721C2 |
| NOVEL SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | 2020 |
|
RU2820501C2 |
| CRYSTALLINE FORMS OF {[1-CYANO-5-(4-CHLOROPHENOXY)-4-HYDROXY-ISOQUINOLINE-3-CARBONYL]-AMINO}-ACETIC ACID | 2014 |
|
RU2666144C2 |
| NOVEL POLYMORPHS AND SALTS | 2011 |
|
RU2573384C2 |
| SHORT-TERM ACTION BENZODIAZEPINE SALTS AND POLYMORPHS THEREOF | 2007 |
|
RU2470935C2 |
| SOLID FORMS OF CEFTOLOZANE | 2014 |
|
RU2703457C2 |
| SOLID FORMS OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS FOR USE THEREOF | 2016 |
|
RU2743349C2 |
| NOVEL CRYSTALLINE FORMS OF N-[-2[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6-{[(1R,2S)-2,3-DIHYDROXY-1-METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZATIDINE-SULPHONAMIDE | 2011 |
|
RU2548044C2 |
| 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)ETHYL]-2-ETHYL BENZYL]AZETIDINE-3-CARBOXYLIC ACID HEMIFUMARATE SALT | 2009 |
|
RU2518114C2 |
